VeriTeQ Enhances its Patent Portfolio by Filing Two New Patents to Protect its Position as a Leader

VeriTeQ Enhances its Patent Portfolio by Filing Two New Patents to Protect its Position as a Leader in Breast Implant Identification and Safety Technologies

DELRAY BEACH, Fla.--(BUSINESS WIRE)-- Digital Angel Corporation ("Digital Angel" or the "Company") (OTC Markets: DIGA), a provider of implantable medical device identification and radiation dose measurement technologies, following its recent share exchange with VeriTeQ Acquisition Corporation ("VeriTeQ"), announced today that VeriTeQ has enhanced its patent portfolio by filing two new patents with the U.S. Patent and Trademark Office in order to protect its position as a leader in breast implant identification and safety technologies.

The first patent is for VeriTeQ's temperature-resistant microchip, designed specifically to withstand high temperatures during sterilization in the manufacturing of breast implants and other implantable medical devices. The second patent covers the process of using the Company's temperature-resistant microchip in the manufacturing of a breast implant.

VeriTeQ is working with implantable medical device manufacturers in the U.S. and abroad to incorporate its FDA cleared passive radio frequency identification ("RFID") microchip, referred to as "Q Inside Safety Technology," within breast implants and other medical devices to enable the devices to be quickly and safely identified from outside the body. VeriTeQ's Q Inside Safety Technology enables implantable medical device manufacturers to comply with the FDA's Proposed Rule for Unique Device Identification ("UDI"), which contains a direct marking requirement recommended for implantable medical devices because these devices present unique risks that would be better controlled through direct marking (versus simple labeling on the outside of the medical device packaging). The UDI Regulation has been released from the FDA to the White House Office of Management and Budget, and it is anticipated that the UDI Final Regulation will be released in the near future.

"We have chosen to focus initially on the UDI of breast implants due to the global demand for the safe and accurate identification of these devices once inside the body. This demand stems from past recalls of breast implants, particularly the scandal involving Poly Implant Prothese's implants in the European Union," stated Scott R. Silverman, Chairman and Chief Executive Officer of VeriTeQ. "We believe our innovative technology and intellectual property, which we continue to improve upon and protect, puts us in a strong position to help supply safer implantable medical devices for patients."

According to the International Society of Aesthetic Plastic Surgery, the number of breast augmentation procedures performed worldwide in 2011 exceeded 1.2 million.

About Digital Angel and VeriTeQ

Digital Angel, through its VeriTeQ wholly-owned subsidiary, develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

Statements in this press release about our future expectations, including without limitation, the likelihood thatVeriTeQ's Q Inside Safety Technology enables implantable medical device manufacturers to comply with the FDA's Proposed Rule for UDI; the likelihood that the UDI Final Regulation will be released in the near future; the likelihood that the Company's innovative technology and intellectual property, which it continues to improve upon and protect, puts the Company in a strong position to help supply safer implantable medical devices for patients; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the ability to promptly and effectively integrate the businesses of Digital Angel and VeriTeQ; VeriTeQ's ability to target the UDI sector and implantable medical device manufacturers; VeriTeQ's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Digital Angel
Allison Tomek, 561-846-7003
atomek@veriteqcorp.com

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS:

The article VeriTeQ Enhances its Patent Portfolio by Filing Two New Patents to Protect its Position as a Leader in Breast Implant Identification and Safety Technologies originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.